SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body
Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer
(NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving
treatment with Osimertinib